AMRI, which was founded in 1991 as Albany Molecular Research, Inc., is a global contract research and manufacturing company offering its customers fully integrated drug discovery, development, and manufacturing services. The company, with a track record of success spanning over 21 years, has locations in the United States, Europe, and Asia to serve its customers.
The company announced today the hiring of two experts in medicinal and computational chemistry at its research center located at Hyderabad, India. It also announced the completion of the relocation of custom library synthesis resources and capabilities to Hyderabad from its Budapest, Hungary facilities. These two events will provide AMRI additional flexibility to enhance productivity and client service for its global drug discovery operations.
The two new hires are Dr. Srinivas Nanduri, Ph.D. and Dr. Suneel Kumar Bommisetty, Ph.D. Dr. Nanduri was hired as director of Medicinal chemistry in India while Dr. Bommisetty was hired as senior research associate of computational chemistry and will report to Dr. Nanduri. Dr. Nanduri reports directly to the president of India operations, Subramanyam Maddala. These two newly created positions are expected to strengthen AMRI’s capabilities in problem solving medicinal chemistry.
Both new hires bring a high level of medicinal chemistry expertise, drug discovery project management experience, and a strong track record of industry expertise. Dr. Nanduri’s most recent role was research director at Aurigene where he was responsible for execution of supervision of multiple integrated drug discovery projects. He also worked previously at Biocon-BMS Research Center and at one of India’s leading pharmaceutical companies, Dr. Reddy’s Laboratories. Dr. Bommisetty joins the firm from GVK Biosciences and brings more than eight years of computational chemistry experience.
For additional information about AMRI, please visit the company’s website at www.amriglobal.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
